Chronic treatment of mice with leukemia inhibitory factor does not cause adverse cardiac remodeling but improves heart function

European Cytokine Network

Volumn 23, Issue 4, 2012, Pages 197-

  Zgheib, Carlos ^a   Zouein, Fouad Anthony ^a   Kurdi, Mazen ^a,b   Booz, George Warren ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b LEBANESE UNIVERSITY   (Lebanon)

Author keywords

Cardiac dysfunction; Cardiac hypertrophy; Cardiac remodeling; Cardiac repair; Cytokine; JAK STAT signaling

Indexed keywords

LEUKEMIA INHIBITORY FACTOR; MICRORNA; MONOCYTE CHEMOTACTIC PROTEIN 1; STAT3 PROTEIN; CCL2 PROTEIN, HUMAN; CYTOKINE; LIF PROTEIN, MOUSE; MANGANESE SUPEROXIDE DISMUTASE; PROTEIN BCL X; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIASTOLE; ECHOCARDIOGRAPHY; HEART EJECTION FRACTION; HEART FUNCTION; HEART INJURY; HEART MUSCLE FIBROSIS; HISTOLOGY; HYPERTROPHY; MALE; MOUSE; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; SYSTOLE; WEIGHT REDUCTION; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; CARDIAC DYSFUNCTION; CARDIAC REMODELING; CARDIAC REPAIR; CARDIOMEGALY; DRUG EFFECT; ENZYMOLOGY; FIBROSIS; GENE EXPRESSION REGULATION; GENETICS; HEART; HEART FUNCTION TEST; HEART STROKE VOLUME; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; JAK STAT SIGNALING; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; STAINING;

CARDIAC DYSFUNCTION; CARDIAC HYPERTROPHY; CARDIAC REMODELING; CARDIAC REPAIR; CYTOKINE; JAK STAT SIGNALING;

ANIMALS; BCL-X PROTEIN; CARDIOMEGALY; CHEMOKINE CCL2; FIBROSIS; GENE EXPRESSION REGULATION; HEART; HEART FUNCTION TESTS; LEUKEMIA INHIBITORY FACTOR; MALE; MICE; MICE, INBRED C57BL; MICRORNAS; STAINING AND LABELING; STAT3 TRANSCRIPTION FACTOR; STROKE VOLUME; SUPEROXIDE DISMUTASE; VENTRICULAR REMODELING;

MLCS; MLOWN;

EID: 84873727859     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: 10.1684/ecn.2012.0319     Document Type: Article

References (44)

1. Izumi M, Masaki M, Hiramoto Y, et al. Cross-talk between bone morphogenetic protein 2 and leukemia inhibitory factor through ERK 1/2 and Smad1 in protection against doxorubicininduced injury of cardiomyocytes. J Mol Cell Cardiol 2006; 40: 224-33.
2. Negoro S, Kunisada K, Fujio Y, et al. Activation of signal transducer and activator of transcription 3 protects cardiomyocytes from hypoxia/reoxygenation-induced oxidative stress through the upregulation of manganese superoxide dismutase. Circulation 2001; 104: 979-81.
3. Negoro S, Oh H, Tone E, et al. Glycoprotein 130 regulates cardiac myocyte survival in doxorubicin-induced apoptosis through phosphatidylinositol 3-kinase/Akt phosphorylation and Bcl-xL/caspase-3 interaction. Circulation 2001; 103: 555-61.
4. Wang F, Seta Y, Baumgarten G, Engel DJ, Sivasubramanian N, Mann DL. Functional significance of hemodynamic overload-induced expression of leukemia-inhibitory factor in the adult mammalian heart. Circulation 2001; 103: 1296-302.
5. Nelson SK, Wong GH, McCord JM. Leukemia inhibitory factor and tumor necrosis factor induce manganese superoxide dismutase and protect rabbit hearts from reperfusion injury. J Mol Cell Cardiol 1995; 27: 223-229.
6. Zou Y, Takano H, Mizukami M, et al. Leukemia inhibitory factor enhances survival of cardiomyocytes and induces regeneration of myocardium after myocardial infarction. Circulation 2003; 108: 748-53.
7. Funamoto M, Fujio Y, Kunisada K, et al. Signal transducer and activator of transcription 3 is required for glycoprotein 130-mediated induction of vascular endothelial growth factor in cardiac myocytes. J Biol Chem 2000; 275: 10561-6.
8. Fujio Y, Kunisada K, Hirota H, Yamauchi-Takihara K, Kishimoto T. Signals through gp130 upregulate bcl-x gene expression via STAT1-binding cis-element in cardiac myocytes. J Clin Invest 1997; 99: 2898-905.
9. Miyamoto S, Murphy AN, Brown JH. Akt mediates mitochondrial protection in cardiomyocytes through phosphorylation of mitochondrial hexokinase-II. Cell Death Differ 2008; 15: 521-9.
10. Miyamoto S, Purcell NH, Smith JM, et al. PHLPP-1 negatively regulates Akt activity and survival in the heart. Circ Res 2010; 107: 476-84.
11. Downey JM, Davis AM, Cohen MV. Signaling pathways in ischemic preconditioning. Heart Fail Rev 2007; 12: 181-8.
12. Wu R, Wyatt E, Chawla K, et al. Hexokinase II knockdown results in exaggerated cardiac hypertrophy via increased ROS production. EMBO Mol Med 2012; 4: 633-46.
13. Nakaoka Y, Nishida K, Fujio Y, et al. Activation of gp130 transduces hypertrophic signal through interaction of scaffolding/docking protein Gab1 with tyrosine phosphatase SHP2 in cardiomyocytes. Circ Res 2003; 93: 221-9.
14. Nicol RL, Frey N, Pearson G, Cobb M, Richardson J, Olson EN. ActivatedMEK5induces serial assembly of sarcomeres and eccentric cardiac hypertrophy. EMBO J 2001; 20: 2757-67.
15. Nagai T, Tanaka-Ishikawa M, Aikawa R, et al. Cdc42 plays a critical role in assembly of sarcomere units in series of cardiac myocytes. Biochem Biophys Res Commun 2003; 305: 806-10.
16. Fujio Y, Matsuda T, Oshima Y, et al. Signals through gp130 upregulate Wnt5a and contribute to cell adhesion in cardiac myocytes. FEBS Lett 2004; 573: 202-6.
17. Takahashi E, Fukuda K, Miyoshi S, et al. Leukemia inhibitory factor activates cardiac L-Type Ca2+ channels via phosphorylation of serine 1829 in the rabbit Cav1.2 subunit. Circ Res 2004; 94: 1242-8.
18. Florholmen G, Aas V, Rustan AC, et al. Leukemia inhibitory factor reduces contractile function and induces alterations in energy metabolism in isolated cardiomyocytes. J Mol Cell Cardiol 2004; 37: 1183-93.
19. Florholmen G, Andersson KB, Yndestad A, Austbø B, Henriksen UL, Christensen G. Leukaemia inhibitory factor alters expression of genes involved in rat cardiomyocyte energy metabolism. Acta Physiol Scand 2004; 180: 133-42.
20. Florholmen G, Thoresen GH, Rustan AC, Jensen J, Christensen G, Aas V. Leukaemia inhibitory factor stimulates glucose transport in isolated cardiomyocytes and induces insulin resistance after chronic exposure. Diabetologia 2006; 49: 724-31.
21. 2+]i transient, and APD increase in cardiomyocytes. J Mol Cell Cardiol 2007; 43: 710-6.
22. Hiraoka E, Kawashima S, Takahashi T, Rikitake Y, Hirase T, Yokoyama M. PI 3-kinase-Aktp70 S6 kinase in hypertrophic responses to leukemia inhibitory factor in cardiac myocytes. Kobe J Med Sci 2003; 49: 25-37.
23. Meléndez GC, McLarty JL, Levick SP, Du Y, Janicki JS, Brower GL. Interleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in rats. Hypertension 2010; 56: 225-31.
24. Vasan RS, Sullivan LM, Roubenoff R, et al. Framingham Heart Study. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation 2003; 107: 1486-91.
25. Gullestad L, Aukrust P. Reviewof trials in chronic heart failure showing broad-spectrum anti-inflammatory approaches. Am J Cardiol 2005; 95: 17C-23C.
26. Oikonomou E, Tousoulis D, Siasos G, Zaromitidou M, Papavassiliou AG, Stefanadis C. The role of inflammation in heart failure: new therapeutic approaches. Hellenic J Cardiol 2011; 52: 30-40.
27. Zgheib C, Zouein FA, Kurdi M, Booz GW. Differential STAT3 Signaling in the Heart: Impact of Concurrent Signals and Oxidative Stress. JAK-STAT 2012; 1: 102-11.
28. Metcalf D, Nicola NA, Gearing DP. Effects of injected leukemia inhibitory factor on hematopoietic and other tissues in mice. Blood 1990; 76: 50-6.
29. Cheon H, Yang J, Stark GR. The functions of signal transducers and activators of transcriptions 1 and 3 as cytokine-inducible proteins. J Interferon Cytokine Res 2011; 31: 33-40.
30. Matthys P, Billiau A. Cytokines and cachexia. Nutrition 1997; 13: 763-70.
31. Kohanbash G, Okada H. MicroRNAs and STAT interplay. Semin Cancer Biol 2012; 22: 70-5.
32. Mendell JT. miRiad roles for the miR-17-92 cluster in development and disease. Cell 2008; 133: 217-22.
33. Topkara VK, Mann DL. Role of microRNAs in cardiac remodeling and heart failure. Cardiovasc Drugs Ther 2011; 25: 171-82.
34. Tan JH, Canals M, Ludeman JP, et al. Design and receptor interactions of obligate dimeric mutant of chemokine monocyte chemoattractant protein-1 (MCP-1). J Biol Chem 2012; 287: 14692-702.
35. Yao Y, Tsirka SE. The C terminus of mouse monocyte chemoattractant protein 1 (MCP1) mediates MCP1 dimerization while blocking its chemotactic potency. J Biol Chem 2010; 285: 31509-16.
36. Kanazawa H, Ieda M, Kimura K, et al. Heart failure causes cholinergic transdifferentiation of cardiac sympathetic nerves via gp130-signaling cytokines in rodents. J Clin Invest 2010; 120: 408-21.
37. Morimoto H, Hirose M, Takahashi M, et al. MCP-1 induces cardioprotection against ischaemia/reperfusion injury: role of reactive oxygen species. Cardiovasc Res 2008; 78: 554-62.
38. Morimoto H, Takahashi M, Izawa A, et al. Cardiac overexpression of monocyte chemoattractant protein-1 in transgenic mice prevents cardiac dysfunction and remodeling after myocardial infarction. Circ Res 2006; 99: 891-9.
39. Bonauer A, Dimmeler S. The microRNA-17-92 cluster: still a miRacle? Cell Cycle 2009; 8: 3866-73.
40. Bonci D. MicroRNA-21 as therapeutic target in cancer and cardiovascular disease. Recent Pat Cardiovasc Drug Discov 2010; 5: 156-61.
41. Cheng Y, Ji R, Yue J, et al. MicroRNAs are aberrantly expressed in hypertrophic heart: do they play a role in cardiac hypertrophy? Am J Pathol 2007; 170: 1831-40.
42. Tatsuguchi M, Seok HY, Callis TE, et al. Expression of microRNAs is dynamically regulated during cardiomyocyte hypertrophy. J Mol Cell Cardiol 2007; 42: 1137-41.
43. 2-induced injury on cardiac myocytes via its target gene PDCD4. J Mol Cell Cardiol 2009; 47: 5-14.
44. Song XW, Li Q, Lin L, et al. MicroRNAs are dynamically regulated in hypertrophic hearts, and miR-199a is essential for the maintenance of cell size in cardiomyocytes. J Cell Physiol 2010; 225: 437-43.